KGRKJGETMRETU895U-589TY5MIGM5JGB5SDFESFREWTGR54TY
Server : Apache/2.4.62
System : FreeBSD fbsdweb2.web.rcn.net 14.1-RELEASE FreeBSD 14.1-RELEASE releng/14.1-n267679-10e31f0946d8 GENERIC amd64
User : www ( 80)
PHP Version : 8.3.8
Disable Function : NONE
Directory :  /domains/bluerae/clients/mipi/prototype8/molecular/

Upload File :
current_dir [ Writeable ] document_root [ Writeable ]

 

Current File : /domains/bluerae/clients/mipi/prototype8/molecular/pt.html
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />

<meta name="description" content="Molecular Insight is focused on critical diagnostic and therapeutic needs of the prostate cancer patient." />
<meta name="keywords" content="prostate cancer, prostate cancer detection, prostate cancer treatment, small-molecule, radiotherapy, metastatic prostate cancer" />

<title>Molecular Insight: Proprietary Technologies</title>

<link href="../stylesmenu.css" rel="stylesheet" type="text/css" />
<link href="../styles.css" rel="stylesheet" type="text/css" />

</head>

<body>

<div id="container">

<!-- LEFT CONTAINER - CONTAINS ALL ELEMENTS ON LEFT HALF OF PAGE, EACH POSITIONED ABSOLTELY -->
<div id="leftcontainer">
<div id="logo"><a href="../index.html"><img src="../images/logo.gif" width="241" height="315" alt="Molecult Insight Home" /></a></div>
<div id="mininav"><a href="../about/contact.html">CONTACT US</a> ::  <a href="../search/sitemap.html">SITEMAP</a> ::  <a href="../search/index.html">SEARCH</a></div>
<div id="pagemenu">
  <p class="currentsection">Molecular Medicine</p>
  <ul>
    <li><a href="../molecular/index.html">Overview</a></li>
    <li><a href="../molecular/mip.html">Molecular Imaging <br />Pharmaceuticals</a></li>
    <li><a href="../molecular/tr.html">Targeted Radiotherapeutics</a></li>
    <li><a href="../molecular/pt.html" class="current">Proprietary Technologies</a></li>
  </ul>
</div>
<div id="photolarge"><img src="images/p_pt.jpg" width="241" height="341" alt=" " /></div>
<div id="photosmall"> </div>
<div id="contactinfo">
<p class="address">Molecular Insight Pharmaceuticals, Inc.<br />
  <a href="http://maps.google.com/maps?q=160+Second+Street,+Cambridge,+MA+02142&amp;oe=utf-8&amp;client=firefox-a&amp;hnear=160+2nd+St,+Cambridge,+Massachusetts+02142&amp;gl=us&amp;t=m&amp;z=16" target="_blank" class="softlink">160 Second Street, Cambridge, MA 02142</a><br />
617.492.5554 tel  ::  617.492.5664 fax<br />
<a href="mailto:[email protected]">[email protected]</a><br />
  </p>
</div>
</div><!--close left container-->

<!-- MAIN CONTENT - includes main menu at top -->
<div id="maincontent" >
<div id="mainmenu">
<ul>
    <!--<li style="width: 400px;">&nbsp;</li>-->
    <li><a href="../about/index.html">About Us<span class="separator">::</span></a>
    <ul>
    <li><a href="../about/index.html">Overview</a></li>
    <li><a href="../about/executive.html">Executive Management</a></li>
    <li><a href="../about/board.html">Board of Directors</a></li>
    <li><a href="../about/scientific.html">Scientific Advisory Board</a></li>
    <li><a href="../about/careers.html">Careers</a></li>
    <!-- <li><a href="../about/MolecularInsight_FactSheet.pdf">Fact Sheet (PDF)</a></li>
    <li><a href="../about/video.html">Corporate Video</a></li>-->
    <li><a href="../about/licensing.html">Licensing</a></li><img src="../images/menu_bottom.png" width="168" height="8" alt=" " class="menubottom" />
    </ul>
    </li>
    <li><a href="../molecular/index.html" class="current">Molecular Medicine<span class="separator">::</span></a>
    <ul>
    <li><a href="../molecular/index.html">Overview</a></li>
    <li><a href="../molecular/mip.html">Molecular Imaging <br />Pharmaceuticals</a></li>
    <li><a href="../molecular/tr.html">Targeted Radiotherapeutics</a></li>
    <li><a href="../molecular/pt.html">Proprietary Technologies</a></li><img src="../images/menu_bottom.png" width="168" height="8" alt=" " class="menubottom" />
    </ul></li>
    <li><a href="../pipeline/index.html">Pipeline<span class="separator">::</span></a>
    <ul>
    <li><a href="../pipeline/index.html">Overview</a></li>
    <li><a href="../pipeline/prostate.html">Prostate Cancer</a></li>
    <li><a href="../pipeline/diagnostic.html">Diagnostic</a></li>
    <li><a href="../pipeline/therapeutic.html">Therapeutic</a></li>
    <li><a href="../pipeline/sci_pres.html">Presentations </a></li>
    <li><a href="../pipeline/sci_pub.html"> Publications</a></li><img src="../images/menu_bottom.png" width="168" height="8" alt=" " class="menubottom" />
    </ul></li>
    <li><a href="../intheclinic/index.html">In the Clinic<span class="separator">::</span></a>
<ul>
    <li><a href="../intheclinic/index.html">Overview</a></li>
<img src="../images/menu_bottom.png" width="168" height="8" alt=" " class="menubottom" />
    </ul></li><li><a href="../media/index.html">Media Room</a>
    <ul>
    <li><a href="../media/index.html">Overview</a></li>
    <li><a href="../media/releases.html">Press Releases</a></li>
    <li><a href="../media/clips.html">Press Clips</a></li>
<img src="../images/menu_bottom.png" width="168" height="8" alt=" " class="menubottom" />
    </ul>
    </li>
    </ul>
    </div>

  <h1 class="pagehead"><span class="currentsection"></span>Proprietary Technologies</h1>
  <p class="introtext">Molecular Insight has developed proprietary platform technologies that allow radiochemistry to be integrated into the medicinal chemistry stage of drug discovery. </p>
  <p>As such, libraries of compounds can be screened which are chemically or structurally equivalent to radiolabeled compounds.  This integrated approach allows for the rapid synthesis, screening and deconvolution of large numbers of compounds, while ensuring that the radiolabeling platform is compatible with subsequent development and manufacturing activities.</p>
  <p>Molecular Insight’s core proprietary technologies include SAAC™ Technology, Ultratrace™ Technology, and SAACQ™ Technology.  These technologies drive development of our current portfolio and will enable the discovery and development of future molecular imaging pharmaceuticals and targeted radiotherapeutic candidates. </p>
  <h2>SAAC™ Technology </h2>
  <p>The ability to reliably and robustly incorporate medically useful radioactive metals into biologically relevant targeting molecules is critical to the design of effective radiopharmaceuticals for molecular imaging and targeted radiotherapy.  Single Amino Acid Chelate, or SAAC™, is our unique metal binding chemistry platform technology.  It represents a new family of compounds with superior metal binding properties for leading radionuclides used for molecular imaging and radiotherapy, namely technetium-99m, rhenium-186 and rhenium-188.  This technology incorporates a metal binding, or chelating, group that can rapidly and efficiently bind to technetium or rhenium for diagnostic and therapeutic applications, and an amino acid portion that allows it to be incorporated into any peptide sequence through the use of conventional peptide chemistry.  Molecular Insight’s molecular imaging radiopharmaceutical product candidate, <sup>99m</sup>Tc-MIP-1404, is based on this technology.</p>
  <h2>Ultratrace™ TechnologY</h2>
  <p>Our Ultratrace™ technology is a proprietary solid-phase radiolabeling technology that enables the development of ultrapure radiopharmaceuticals which are devoid of unnecessary cold contaminants, thereby enhancing safety, specificity, and potency.  Cold contaminants are non-radioactive, or unlabeled targeting molecules, which may potentially induce unnecessary side effects and suboptimal efficacy by competing with radiolabeled targeting molecules for binding to a limited number of receptor target sites.</p>
  <h2>SAACQ™ Technology </h2>
  <p>Two widely employed techniques for visualizing specific biological processes are fluorescence microscopy and radioisotope imaging.  Different from current technologies, our new fluorescence-based technology called SAACQ™ enables the visualization of radiopharmaceuticals interacting with cellular structures.  This advanced technology promises to accelerate the development of targeted radiopharmaceuticals and molecular imaging pharmaceuticals by allowing live cell activity to be viewed by fluorescent microscopy.</p>
  <h3>&nbsp;</h3>

<!-- FOOTER - contained within main content div -->
<div id="footer">
<p>Copyright © 2012 Molecular Insight. All Rights Reserved.  ::  <a href="../privacy.html">Privacy Policy</a> :: <a href="../terms.html">Terms of Use</a> :: <a href="../index.html"><strong>Home</strong><br />
  </a>Design: <a href="http://www.bluerae.com/">Bluerae Creative</a></p>
</div>


</div>

</div><!--close container-->

</body>
</html>

Anon7 - 2021